EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition

Sergey Karakashev, Takeshi Fukumoto, Bo Zhao, Jianhuang Lin, Shuai Wu, Nail Fatkhutdinov, Pyoung Hwa Park, Galina Semenova, Stephanie Jean, Mark G. Cadungog, Mark E. Borowsky, Andrew V. Kossenkov, Qin Liu, Rugang Zhang

Research output: Contribution to journalArticlepeer-review

Abstract

Karakashev et al. show that CARM1 promotes EZH2-mediated epigenetic silencing of the shieldin complex protein MAD2L2. Inhibition of EZH2 induces MAD2L2 expression and non-homologous end-joining in CARM1-high, homologous recombination proficient ovarian carcinoma cells, sensitizing them to PARP inhibitors.

Original languageEnglish
Pages (from-to)157-167.e6
JournalCancer Cell
Volume37
Issue number2
DOIs
StatePublished - Feb 10 2020

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Keywords

  • BAF155
  • CARM1
  • EZH2 inhibitors
  • MAD2L2 (REV7)
  • PARP inhibitors
  • SWI/SNF
  • epithelial ovarian cancer
  • homologous recombination (HR)
  • non-homologous end-joining (NHEJ)
  • polycomb repressive complex 2 (PRC2)
  • shieldin

Fingerprint

Dive into the research topics of 'EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition'. Together they form a unique fingerprint.

Cite this